NCNathan Congdon

Nathan Congdon

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Nathan Congdon has a total of 866 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Evaluating the effect of spectacle correction for refractive errors and presbyopia on cognitive function in rural older adults in China: protocol for a randomised, parallel-group, superiority trial

    by Liang Lv, Fan Yang, Meng Li, Jun Xiao, Houjiang Yang, Dongfeng Li, Chunmei Hu, Yiwen Wang, Xiao Xiao, Ling Jin, et al.

    Background: Vision impairment and mild cognitive impairment are highly prevalent in ageing rural populations of low- and middle-income countries. Observational studies suggest that vision correction may slow cognitive decline, but robust causal evidence—particularly from rural China—is lacking, despite an ongoing randomised controlled trial (RCT) in India. Our RCT will evaluate whether providing near and/or distance vision correction can slow cognitive decline among older adults in rural China, generating context-specific evidence to guide national policy and global healthy ageing strategies. Methods: This study is designed as an assessor-blind, parallel-group, individually RCT. A total of 964 participants (482 per arm) aged 60–79 years with correctable refractive error-related visual impairment at distance and/or near (presenting visual acuity <6/12 in the better-seeing eye, improving to ≥6/7.5 in either eye with spectacle and/or near visual acuity <6/12 at 40 cm when measured binocularly, improving to ≥6/7.5 in either eye with spectacle), rural household registration, normal hearing (defined as a hearing threshold <40 dB in at least one ear, assessed using the HearX HearTest) and Mini-Mental State Examination, Second Edition, Simplified Chinese version scores above education-specific cut-offs will be enrolled. After comprehensive eye examinations at township health centres or village clinics, intervention participants will receive distance, near or bifocal spectacles while controls will receive a prescription and spectacles at trial closeout. The primary outcome is the change in global cognitive function from baseline to the 36-month follow-up, assessed using the Chinese version of the Montreal Cognitive Assessment Basic, with and without adjustment for baseline score, age, gender, education and other potential confounders. Ethics and dissemination: The protocol is approved by the Institutional Review Board of West China School of Public Health and West China Fourth Hospital, Sichuan University, China (approval number: (HXSY-BEC-S2026005)). Results will be published in a peer-reviewed journal and presented at scientific meetings. Trial registration number: NCT06836440 , 21 April 2025, ( https://clinicaltrials.gov/study/NCT06836440 ).

  • Open Access

    Diagnostic Accuracy of Cybersight AI for Glaucoma Detection: Sensitivity, Specificity, and ROC Analysis

    by Nha Uyen Phan, Trong Van Pham, Kim Thanh Doan, Le Phuc Hoang, Nhu Vinh Tuyen Pham, Minh Tuan Nguyen, Quoc Tung Mai, Nicolas Jaccard, Nathan Congdon

    Glaucoma is a chronic, progressive optic neuropathy and a leading cause of irreversible blindness worldwide. Early detection is crucial but is often limited by nonspecific clinical signs and the need for specialist expertise. Artificial intelligence (AI), particularly deep learning, has shown promise for glaucoma detection from ophthalmic images. This study independently validated an existing third-party AI tool, Cybersight AI, powered by the Visulytix Pegasus engine, for detecting primary glaucoma. No new algorithm was developed or proposed. A cross-sectional diagnostic accuracy study was conducted on 229 eyes from 121 patients, including 133 eyes with primary glaucoma and 96 controls, at Hue Central Hospital between December 2024 and September 2025. Fundus photographs were analyzed using the Cybersight AI platform, which estimated the vertical cup-to-disc ratio and generated a binary glaucoma referral recommendation. AI outputs were compared with diagnoses established by ophthalmologists using an expert multimodal clinical reference standard. Diagnostic performance was assessed using sensitivity, specificity, positive and negative predictive values, and the area under the receiver operating characteristic curve (AUC). At its default operating point, Cybersight AI achieved 51.9% sensitivity (95% CI 43.5–60.2) and 90.6% specificity (95% CI 83.1–95.0), with an AUC of 0.744 (95% CI 0.682–0.807). Positive and negative predictive values were 88.5% and 57.6%, respectively. The Youden-optimal cut-off was 10%, yielding 60.9% sensitivity and 85.4% specificity. Cybersight AI demonstrated moderate discrimination, high specificity, and modest sensitivity at its default binary setting in this Vietnamese tertiary-care cohort. It may serve as a screening or triage adjunct, although context-specific thresholding and further external validation are required before broad clinical deployment. Limitations include the single-center convenience sample, within-patient clustering, and comparison of a fundus-only index test against a multimodal reference standard. Future studies should prioritize multicenter validation in Vietnamese settings and comparison with expert fundus assessment alone.

  • Persistence of severe global sex-based inequalities in the burden of visual impairment

    by Xiao Guo, Yanping Chen, Ruilin Xiong, Shuxi Zhuo, Huangdong Li, Ziyu Zhu, Zhuoting Zhu, Lei Zhang, Wenyong Huang, Nathan Congdon, et al.

    Background/aims: Sex-based disparities in vision impairment are a major global health concern. This study quantifies these disparities across major blinding diseases and assesses their association with national-level gender inequality. Methods: In this repeated ecological analysis of Global Burden of Disease (GBD) 2023 data, we analysed sex-disaggregated age-standardised years lived with disability (YLD) rates and prevalence for major blinding diseases. Temporal trends were assessed using average annual per cent change (AAPC). Linear regression examined associations between sex differences and the Gender Development Index (GDI) and Gender Inequality Index (GII). Projections were performed using a Bayesian age-period-cohort model. Results: From 1990 to 2023, sex disparities persisted, with a higher AAPC in females than males (0.08% vs −0.06%). In 2023, females had higher YLD rates than males for blindness and vision loss (BVI) (300.9 vs 262.8 per 100 000; +14.5%), cataract (95.1 vs 75.0; +26.7%) and age-related macular degeneration (6.9 vs 5.8; +18.0%), while glaucoma was higher in males. The largest female excess for BVI was in South Asia (difference 69.9 per 100 000). Higher GII and lower GDI were significantly associated with larger sex disparities (β=34.3 per unit GII increase; β=−197.0 per unit GDI increase, all p<0.001). Without targeted intervention, disparities are projected to persist or widen by 2040. Conclusion: Global sex disparities in vision impairment remained substantial from 1990 to 2023 and are projected to continue. The strong association with GDI and GII indicates these disparities are modifiable and linked to structural factors. Gender-sensitive policies are needed to achieve equity in eye health.

  • Global temporal trends of DR-related blindness and vision loss from 1990 to 2021: an age-period-cohort analysis of the contributions of type 1 and type 2 diabetes

    by Zhiqiang Guan, Yongyi Li, Yuancun Li, Zhen Qian, Yali Du, Shengjie Yin, Binyao Chen, Hongxi Wang, Jiao Jiang, Hailiu Chen, et al.

    Background and aims: The current study aims to investigate how age, period and cohort effects have shaped the patterns of diabetic retinopathy-related vision loss globally, distinguishing between loss associated with type 1 versus 2 diabetes. Methods: A secondary analysis of data from the Global Burden of Disease (GBD) 2021 study was conducted by using estimates of blindness and vision loss due to DR across different socio-demographic index (SDI) categories. Age-standardised prevalence rates, relative percentage changes, net drift and local drift were analysed. Findings: Globally, age-standardised prevalence (ASPR) of diabetes-related blindness and vision loss rose from 48.8 per 100 000 in 1990 to 67.3 per 100 000 in 2021, with type 1 diabetes-related blindness and vision loss ASPR showing a modest decrease (from 1.8 to 1.7 per 100 000). The highest relative increase was recorded in the high SDI group (45.8%). For Type 1 diabetes, low-middle and low SDI groups exhibited more pronounced declines in associated ASPR. Increasing ASPR with advancing age was consistent across SDI groups though less pronounced for type 1 than type 2 diabetes. Unfavourable period and cohort effects were observed for type 2 but not type 1-related blindness and vision loss risk. High-middle SDI and middle SDI groups showed the most notable increase in period and cohort effect, whereas low-middle and low SDI groups experienced favourable period and cohort risks during the study duration. Conclusions: Substantially different trends were observed for ASPR, period and cohort effects in recent decades for type 1 versus type 2 diabetes across different SDI.

  • Socioeconomic inequalities in self-reported vision impairment among middle-aged and older adults in China: a national longitudinal study from 2011 to 2018

    by Kun Xiong, Fengping Zhao, Dengming Zhou, Xuanli Zheng, Shaodan Zhang, Nathan Congdon, Lu Yang, Yuanbo Liang

    To define temporal trends and socioeconomic inequalities in vision impairment in China. This analysis utilises data from the China Health and Retirement Longitudinal Study, a nationally representative cohort study, which enrolled 10,942, 11,026, 12,717 and 16,095 participants aged ≥45 years across four survey waves conducted in 2011, 2013, 2015 and 2018, respectively. The main outcome was self-reported vision impairment by participants and we analysed trends and socioeconomic inequalities in the prevalence of distance vision impairment (DVI) and near vision impairment (NVI). The age- and sex-adjusted prevalence of DVI and NVI decreased from 23.4% and 25.5% in 2011 to 17.1% and 18.2% in 2018 (P trend < 0.001). Across survey waves, the prevalence of vision impairment was significantly higher among groups of low versus high SES (2018: DVI 12.4% in the high SES group vs. 24.5% in the low SES group; NVI 13.9% in the high SES group vs. 24.3% in the low SES group). The concentration curves and concentration index indicate that socioeconomic inequality in vision impairment has persisted, that inequality in DVI remained stable (absolute value for concentration index: 0.175 in 2011; 0.182 in 2018) and that inequality in NVI widened (absolute value for concentration index: 0.069 in 2011; 0.142 in 2018). This population-based study found a significant reduction in vision impairment in China from 2011 to 2018. Nonetheless, SES inequality in vision impairment persists without narrowing. Prevention and management strategies for vision impairment must target low SES populations to promote equality in healthcare opportunities.

  • Eyes of Africa: The Genetics of Blindness. Baseline characteristics, ocular features, and associations with glaucoma in continental Africans

    by Adeyinka Ashaye, Olusola Olawoye, Kelsey V. Stuart, Tarela Sarimiye, Chimdi Chuka-Okosa, Nkiru Kizor-Akaraiwe, Ugbede Idakwo, Naa Naamuah Tagoe, Kwesi Nyan Amissah-Arthur, Kuburat O. Adenrele, et al.

    Importance Glaucoma is the leading cause of irreversible blindness worldwide, with disproportionately high prevalence and severity in Africans. Objective To characterise the baseline phenotypic findings and glaucoma-related ocular features of participants with primary open-angle glaucoma (POAG, cases) and non-glaucoma controls and to report sociodemographic and medical associations of POAG in the cohort. Design Multicentre, cross-sectional study. Participants 9418 adults (5189 POAG cases; 4229 controls) recruited from 16 centres in Nigeria, Ghana and Malawi. Methods Standardised demographic, medical and ophthalmic data were collected, including visual acuity, intraocular pressure (IOP), optic disc evaluation, visual fields and central corneal thickness. Main outcome measures Glaucoma severity, visual impairment (VI) and sociodemographic/medical associations of POAG. Results Compared to controls, cases were older (mean age 63.9 years vs 61.4 years, P < 0.001) and more likely to be male (57.4% vs 45.2%, P < 0.001). Three-quarters of cases (76.8%) were classified as having severe glaucoma in at least one eye at recruitment, with a third (34.4%) suffering severe VI or blindness. The leading causes of VI in controls were cataract (65.0%) and uncorrected refractive error (13.8%). POAG was significantly associated with older age, male sex, higher level of education, unemployment, history of alcohol consumption, African trypanosomiasis, higher maximum IOP and a positive family history of glaucoma. Conclusion There is a significant glaucoma disease burden in sub-Saharan Africa. Further analyses of the cohort will identify genetic determinants of these clinical findings and reinforce the urgent need for public health interventions in sub-Saharan Africa.

  • Open Access

    Low concentration atropine eye drops and progression of myopia in children: multicentre placebo controlled, double masked, randomised trial in the UK (CHAMP-UK)

    by Augusto Azuara-Blanco, Nicola S Logan, Emma McConnell, Stephanie Kearney, Gaynor Kirk, Susie Jones, Cliona McDowell, Lynn Murphy, Gerard O’HAnlon, Margaret McFarland, et al.

    Objectives: To evaluate the efficacy and safety of low concentration atropine eye drops for reducing progression of myopia in children in the UK. Design: Multicentre, double masked, superiority, placebo controlled, randomised trial. Setting: National Health Service hospital eye services and academic institutions at five UK centres. Participants: 289 children aged 6-12 years with myopia between −0.50 and −10.0 dioptres (D). Participants were allocated in ratio of 2:1 to atropine or placebo. Interventions: One eye drop of preserved atropine 0.01% or placebo daily for two years. Main outcome measures: The primary outcome was spherical equivalent refractive error of both eyes measured by autorefractor under cycloplegia after two years. Secondary outcomes included change in axial length, best corrected distance and near visual acuity, reading speed, pupil diameter, spectacle correction, adverse event rates, quality of life, and tolerability. Outcomes were collected every six months. An electronic monitoring system was used to assess adherence. Results: 192 participants were included in the atropine group and 97 in the placebo group, with an average age of 9.3 years (standard deviation (SD) 1.7 years). 207 (72%) reported white ethnicity, 161 (56%) were girls, and the mean level of myopia was −2.87 D (SD 1.71 D). A total of 235 (81%) participants completed the study, with primary outcome data available for 230 (80%) participants: 151 (79%) in the atropine group and 79 (81%) in the placebo group. Atropine eye drops were more effective than placebo in reducing myopia progression (mean difference 0.33 D, 95% confidence interval (CI) 0.17 to 0.49 D, P<0.001). Prespecified subgroup analyses did not show differences according to age, ethnicity, sex, or severity of myopia. Changes in central axial length were significantly less in the atropine group versus placebo group: mean difference 0.14 mm (95% CI 0.07 to 0.21, P<0.001). There were no differences in other secondary outcomes, except pupil diameter, which was greater in the atropine group (0.36 mm, 95% CI 0.17, 0.55, P<0.001), and no differences in frequency of adverse events or in tolerability measures. No serious adverse events were related to the trial drugs. Conclusions: Low concentration atropine (0.01%) eye drops significantly reduced progression of myopia and were well tolerated compared with placebo in children in the UK. Trial registration: ISRCTN registry ISRCTN99883695 , ClinicalTrials.gov NCT03690089 .


  • Trends of blindness and visual impairment in individuals aged 70 and older

    by Xiao Guo, Yanping Chen, Jingwei Yao, Jiaqi Huang, Ruilin Xiong, Xiaotong Han, Wenyong Huang, Nathan Congdon, Wei Wang

    Background: The global ageing population has heightened the importance of eye health, yet comprehensive assessments of blindness and vision impairment (BVI) burden among older adults remain limited. Using Global Burden of Disease 2021 data, we analysed trends and disparities in BVI and major eye diseases across 204 countries and territories from 1990 to 2021 among adults aged ≥70 years. Methods: Age-standardised prevalence (ASPR), years lived with disability, and average annual percentage change (AAPC) were estimated for BVI and its leading causes, stratified by age, sex, region and Sociodemographic Index (SDI). Temporal trends were assessed using joinpoint regression. Results: Globally, between 1990 and 2021, the number of BVI cases increased 156% (94.5 to 242 million) with an AAPC of 0.11%. Women experienced a faster rise in ASPR than men (AAPC 0.16% vs 0.11%). Age-specific analysis revealed divergent trends: prevalence rose in the 70–84 age group (peak AAPC 1.02% in 70–74 years) but declined in those ≥85 years (AAPC −0.23% in 85–89 years). With increasing SDI, the prevalence rate for BVI and major blinding eye diseases significantly decreased (p<0.001). Regionally, high-income North America showed the largest ASPR reductions (AAPC −0.30%). Conclusions: Demographic expansion and ageing are the primary drivers of the rise in absolute BVI burden among adults aged ≥70 years since 1990, with persistent inequities across sex and SDI levels. Further country-specific analyses, particularly in settings with limited primary data, will help refine estimates and support future research and service planning.

  • Open Access

    Contextual factors that affect diabetic retinopathy screening uptake at township health units in southern China: a qualitative study with service providers and users

    by Baixiang Xiao, Ving Fai Chan, Carlos Price-Sanchez, Mapa Prabhath Piyasena, Yanfang Wang, Qiong Wan, Nathan Congdon

    Objectives This study aimed to identify the factors that influence access to diabetic retinopathy screening (DRS). Design This is a qualitative case study. Setting Township health units in Shaoguan City, Guangdong Province, China. Participants This study included two representative patient groups (n=15) and five health-staff groups (n=42). Primary and secondary outcome measures Focus group discussions were guided by a female ophthalmologist and other ophthalmology staff to determine the contextual factors influencing DRS uptake in people with diabetes mellitus in Qujiang District, Shaoguan City, southern China. Directly observed treatment and short-course (DOTS) components for the assessment of tuberculosis services were referred to for health structure when themes were extracted using deductive thematic analysis. Results By referring to DOTS components related to the government, case detection, treatment, drug supply and recording system, we identified 31 factors associated with DRS uptake. Among these, six were from the perspective of service users whereas the remaining 25 were related to providers. From these factors, 10 modifiable themes pertained to policy, financing, interdepartmental coordination, hospital preparedness, primary healthcare staff training and public awareness through health education and quality enhancement of public health services. Two unmodifiable factors were also extracted: discomfort from pupil dilation during the examination and long travel distance to the facility. Conclusions This analysis identified contextual factors influencing DRS uptake, including policy, financing and public awareness, which, if addressed, could significantly enhance future screening uptake and disease management.


  • Open Access

    PROductivity Study of Presbyopia Elimination in gaRment workers (PROSPER II): a randomised trial on the productivity impact of providing near glasses to Indian garment factory workers

    by Sonia Pant, Sahil Bagwe, Sangeetha Esther, Graeme MacKenzie, Lovemore Nyasha Sigwadhi, Winston D Prakash, Ving Fai Chan, Smit Gade, Simranjeet Dhir, Saumya Joshi, et al.

    Background Correction for presbyopia, the world’s most common cause of vision impairment, significantly improves productivity in agriculture and crafts. However, effects on productivity in manufacturing remain unstudied. Methods PROSPER II was an individually randomised, investigator-masked, controlled trial conducted in Karnataka, India. Eligible garment factory workers aged ≥35 years with presbyopia (better-eye near vision N6.3 or worse (Snellen 6/12), correctable to N4 (Snellen 6/7.5)) and not owning glasses were randomised (1:1) to intervention (immediate delivery of glasses suited to working distance) or control (identical glasses delivered at endline). The primary outcome was work productivity, defined as the hourly number of items completed, normalised to a factory target rate, over 12 weeks. Secondary outcomes included glasses wear adherence, visual function, and ROI. Results Among 4990 potentially eligible workers, 3648 (73.1%) underwent eye examinations, and 682 (18.7%, mean age 41.0 years, 99.0% female) were enrolled and randomised (intervention: n=344, 50.4%; control: n=338, 49.6%). All participants completed 12-week observation. In panel regression models for the pre-specified primary analysis, intervention group assignment (difference=0.0325, 95% CI 0.006 to 0.060, p=0.017) was significantly associated with greater productivity. Compared with workers in the highest skill grade (A), those in the lowest grade (C) had significantly lower productivity (difference=−0.049, 95% CI −0.087 to −0.011, p=0.011). Glasses increased productivity in the intervention group relative to controls by 5.70% (95% CI 1.04% to 10.4%). Conclusions Free near glasses confer a significant productivity benefit in this factory setting, and are substantially less costly than other successful interventions such as management training. Trial registration number NCT04629820.